secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001725160-25-000104
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis Q1 2025 cash $332.5M; first patient dosed in DENALI Part 2 azenosertib trial
--------------------------------------------------------------------------------

- Cash $332.5M (incl. $12.2M Immunome stock) at March 31, 2025; runway into late 2027.
- First patient dosed in DENALI Part 2a for azenosertib in Cyclin E1+ platinum-resistant ovarian cancer.
- Topline data from DENALI Part 2 expected by year-end 2026; potential for accelerated approval.
- R&D expenses $27.2M vs $49.6M YoY; total operating expenses $45.6M including $7.8M restructuring.
- Prior Part 1b data: ORR 34.9%, median DOR 6.3 months in evaluable Cyclin E1+ PROC patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516025000104/0001725160-25-000104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516025000104/zntl-20250514.htm
  HTML page:      https://secwatch.observer/filing/0001725160-25-000104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer